Changes in the sympathetic innervation of the gut in rotenone treated mice as possible early biomarker for Parkinson’s disease

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Mike Arnhold - , Klinik und Poliklinik für Neurologie (Autor:in)
  • Yanina Dening - , Ludwig-Maximilians-Universität München (LMU), Munich Cluster for Systems Neurology (SyNergy) (Autor:in)
  • Michaël Chopin - , Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne (Autor:in)
  • Esteban Arévalo - , Institut für Anatomie (Autor:in)
  • Mathias Schwarz - , Institut für Anatomie (Autor:in)
  • Heinz Reichmann - , Klinik und Poliklinik für Neurologie, Center for Regenerative Therapies Dresden (CRTD) (Autor:in)
  • Gabriele Gille - , Klinik und Poliklinik für Neurologie (Autor:in)
  • Richard H.W. Funk - , Institut für Anatomie, Center for Regenerative Therapies Dresden (CRTD) (Autor:in)
  • Francisco Pan-Montojo - , Ludwig-Maximilians-Universität München (LMU), Munich Cluster for Systems Neurology (SyNergy) (Autor:in)

Abstract

Introduction: Involvement of the peripheral nervous system (PNS) is relatively common in Parkinson’s disease (PD) patients. PNS alterations appear early in the course of the disease and are responsible for some of the non-motor symptoms observed in PD patients. In previous studies, we have shown that environmental toxins can trigger the disease by acting on the enteric nervous system. Material and methods: Here, we analyzed the effect of mitochondrial Complex I inhibition on sympathetic neuritis in vivo and sympathetic neurons in vitro. Combining in vivo imaging and protein expression profiling. Results: we found that rotenone, a widely used mitochondrial Complex I inhibitor decreases the density of sympathetic neurites innervating the gut in vivo, while in vitro, it induces the redistribution of intracellular alpha-synuclein and neurite degeneration. Interestingly, sympathetic neurons are much more resistant to rotenone exposure than mesencephalic dopaminergic neurons. Conclusion: Altogether, these results suggest that enteric sympathetic denervation could be an initial pre-motor alteration in PD progression that could be used as an early biomarker of the disease.

Details

OriginalspracheEnglisch
Seiten (von - bis)211-222
Seitenumfang12
FachzeitschriftClinical autonomic research
Jahrgang26
Ausgabenummer3
PublikationsstatusVeröffentlicht - 1 Juni 2016
Peer-Review-StatusJa

Externe IDs

PubMed 27178445

Schlagworte

Schlagwörter

  • Biomarker, Constipation, alpha-synuclein pathology, Enteric sympathetic innervation, Parkinson’s disease